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Abstract Tuberculosis has a high morbidity and mortality
worldwide. Mycobacterium tuberculosis (Mtb) has a com-
plex pathophysiology; it is an aerobic bacillus capable of
surviving in anaerobic conditions in a latent state for a very
long time before reactivation to active disease. In the latent
tuberculosis infection, the individual has no clinical evi-
dence of active disease, but exhibits a hypersensitive
response to proteins of Mtb. Only some 5–10 % of latently
infected individuals appear to have reactivation of tuber-
culosis at any one time point after infection, and neither
imaging nor immune tests have been shown to predict
tuberculosis reactivation reliably. The complex pathology
of the organism provides multiple molecular targets for
imaging the infection and targeting therapy. Positron
emission tomography (PET) integrated with computer
tomography (CT) provides a unique opportunity to nonin-
vasively image the whole body for diagnosing, staging and
assessing therapy response in many infectious and inflam-
matory diseases. PET/CT is a powerful noninvasive tool
that can rapidly provide three-dimensional views of disease
deep within the body and conduct longitudinal assessment
over time in one particular patient. Some PET tracers, such
as 18F-fluorodeoxyglucose (18F-FDG), have been found to
be useful in various infectious diseases for detection,
assessing disease activity, staging and monitoring response
to therapy. This tracer has also been used for imaging
tuberculosis. 18F-FDG PET relies on the glucose uptake of
inflammatory cells as a result of the respiratory burst that
occurs with infection. Other PET tracers have also been
used to image different aspects of the pathology or micro-
biology of Mtb. The synthesis of the complex cell mem-
brane of the bacilli for example can be imaged with 11C-
choline or 18F-fluoroethylcholine PET/CT while the uptake
of amino acids during cell growth can be imaged by 30-
deoxy-30-[18F]fluoro-L-thymidine. PET/CT provides a
noninvasive and sensitive method of assessing histopatho-
logical information on different aspects of tuberculosis and
is already playing a role in the management of tuberculosis.
As our understanding of the pathophysiology of tubercu-
losis increases, the role of PET/CT in the management of
this disease would become more important. In this review,
we highlight the various tracers that have been used in
tuberculosis and explain the underlying mechanisms for
their use.
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co-infection despite the availability of relatively cheap and
effective treatment options [1–3]. TB kills 1.5 million
people annually and 9.6 million develop the disease
annually [2]. Most of these deaths are preventable and
therefore the death toll is unacceptably high [4]. It is cur-
rently the second highest infective cause of death world-
wide, only surpassed by human immunodeficiency virus
(HIV). With first cases dating back 9000 years, Mycobac-
terium tuberculosis (Mtb), the causative agent of TB, is one
of the most successful human pathogens of all time [5]. An
increasing proportion of the disease is caused by organisms
insensitive to first-line chemotherapeutic agents (mul-
tidrug-resistant TB [MDR-TB]), first- and some second-
line agents (extensively drug-resistant TB [XDR-TB]) or
even all agents (super-extensive drug-resistant TB [SXDR-
TB]) [6, 7]. This is a major health-care problem worldwide,
since treatment of MDR-TB and even worse XDR-TB is
more challenging and expensive than drug-susceptible TB
[8, 9]. In 95 % of infected individuals, the pathogen is
contained as an asymptomatic latent infection. It has been
estimated that a third of the world’s population harbors
latent TB [10]. The perilous union of TB with HIV also
represents a challenging public health priority as HIV
weakens our most effective barrier against TB, our immune
system, rendering infected individuals more susceptible to
TB [11]. HIV causes a sharp increase in the number of
LTBI patients who progress to active disease [12]. HIV co-
infection also presents diagnostic challenges, potentially
delaying diagnosis and treatment and thereby increasing
morbidity and mortality. As a consequence of this syndetic
interaction, 1.2 million patients with HIV developed TB
and 400,000 people co-infected with TB and HIV died [2].
Despite the enormous burden of TB, current diagnostic
methods are woefully inadequate to meet clinical and
research needs [13].
Pathophysiology
Mtb is an aerobic, obligate intracellular microorganism that
features an unusually complex and thick cell wall. Hall-
marks are long-chain fatty acids called mycolic acids that
surround the bacterial cytoplasmic membrane. The char-
acteristic features of the Mtb include its potential to persist
in host cells, slow growth, complex membrane and intra-
cellular pathogenesis [14]. Mtb persists in host cells in a
dormant, latent or persistent state using a specific genetic
program to respond to stress [15, 16]. This program, for-
merly referred to as Dos Regulon, now DevR activity, is
essential for regulon induction and hypoxic survival of Mtb
[17]. Latency is defined clinically by reactive tuberculin
skin test indicating delayed hypersensitivity to Mtb anti-
gens in the absence of active disease. Persistence is used to
describe to the state in which Mtb survives in host tissues
under various stress conditions. Dormancy refers to a state
in which Mtb remains quiescent within infected cells and is
the result of metabolic and replicative shutdown of the
bacillus using its DevR activity, resulting from the action
of a cell-mediated response of the host that can contain but
not eradicate the infection [18]. The generation time of
actively replicating Mtb in synthetic medium or infected
animals is about 24 and 18 h in humans [19, 20]. This
contributes to the chronic nature of the disease, imposing
lengthy treatment regimens and presenting a formidable
obstacle for researchers. The slow growth of Mtb necessi-
tates long antibiotic therapy rendering treatment suscepti-
ble to failure due to non-adherence [21]. The drugs used
involve unpleasant side effects, and travel to treatment
posts poses economic difficulties to patients. Notably,
treatment failure is the major fuel for the development of
drug resistance [22]. The mycobacterial cell wall is
impermeable to a number of compounds, a feature in part
responsible for inherent resistance to numerous drugs [23].
While mycobacteria are considered Gram positive, the
second membrane executes biological functions compara-
ble to the outer membrane of Gram-negative bacteria, such
as the uptake of small hydrophilic nutrients via special
membrane channels [24]. This protective outer membrane
plays an important role in securing the bacillus’ integrity in
the face of harsh environmental conditions [25]. This outer
compartment of the cell wall consists of both lipids and
proteins, some of which are linked to polysaccharides. The
lipid-linked polysaccharides associated with the outer cell
wall consist of lipoarabinomannan (LAM), lipomannan and
phthiocerol-containing lipids such as phthiocerol dimyco-
cerosate, dimycolyl trehalose (cord factor), sulfolipids and
the phosphatidylinositol mannosides [23]. The pathogenic
effects of some of the lipids include the following: LAM
inhibits T cell proliferation and has bactericidal action of
macrophages amidst other actions. Cord factor, another
glycolipid, inhibits phagosome–lysosome fusion, con-
tributing to the maintenance of the granuloma response. It
is toxic to macrophages, killing them on contact [26, 27].
The success of Mtb as a pathogen lies in its ability to
orchestrate its metabolic pathways to survive in a nutrient-
deficient, acidic, oxidative, nitrosative and hypoxic envi-
ronment inside granulomas or infective lesions and survive
in its host for months to decades in an asymptomatic state,
using DevR activity [28, 29]. The pathogenic potential of
Mtb also depends largely on the type VII secretion system
ESX-1, which is largely responsible for the secretion of
early secreted antigenic target (ESAT-6), culture filtrate
protein (CPF-10) and several other ESX-1 associated pro-
teins. The ESX-1 governs numerous aspects of interaction
between Mtb and the host cell. The ESX-1 system pos-
sesses membrane-damaging activity, allowing Mtb to
escape from Mycobacterium-containing vacuole into host
132 Clin Transl Imaging (2016) 4:131–144
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cell cytosol, where it polymerizes with actin and spreads
from cell to cell, particularly in the later stage of the
infection [30–32].
Transmission and disease progression
Mtb is transmitted as aerosol generated by the respiratory
system, and in 95 % of cases in which the bacilli are
inhaled, a primary infection is established [33]. The cell-
mediated immunity of the host results in either the clearing
of the infection or the restriction of the bacilli inside
granulomas giving rise to a latent TB infection (LTBI),
defined by no visible symptoms of disease, but dormant
and yet alive bacilli in the host. The progress of TB can be
stalled at this stage in some cases by isoniazid—or other
regimens of preventive therapy [34]. This state might last
for the entire life span of the individual or progress to
active TB by reactivation of the existing infection with a
lifetime risk of 5–10 % [35]. In the presence of HIV, this
risk increases with 5 % of LTBI reactivating per year [2].
Reactivation of TB usually occurs at the upper more oxy-
genated lobe of the lung. This can be cured by treatment. In
untreated or poorly treated cases, TB lesions develop
within the lung. These lesions include caseous necrosis,
fibrosis and cavities. The development of cavities close to
airways allows shedding of bacilli into airways and sub-
sequent transmission to other people as aerosol.
Clinical symptoms and risk factors
The classic features of pulmonary TB include chronic
cough, weight loss, fever, night sweats and hemoptysis
[36]. The risk for development of active TB disease is
governed by exogenous and endogenous factors. Exoge-
nous factors accentuate the progression from exposure to
infection. Bacillary load in the sputum of the infected
person, duration and proximity to an infectious TB case are
key factors. Endogenous factors, on the other hand, lead to
the progression from infection to active TB disease [37].
Malnutrition, tobacco smoking and indoor air pollution
from solid fuel have been documented to be most important
risk factors for TB worldwide, followed by HIV infection,
diabetes and excessive alcohol intake [38]. Extrapulmonary
TB occurs in 10–42 % of patients. The occurrence of
extrapulmonary disease depends on the age, presence or
absence of underlying disease, ethnic background, immune
status of the individual and the strain or lineage of Mtb
[37]. The disease may occur in any part of the body and can
mimic a lot of clinical diseases, which potentially delays
the diagnosis. HIV co-infection with TB presents major
challenges to the diagnosis and treatment of TB. The
manifestation of TB varies depending on the immune status
of the host. Soon after HIV infection, TB presentation is
similar to HIV seronegative individuals. As the CD4 count
drops, the presentation becomes atypical, with atypical
pulmonary manifestations and a greater proportion of
patients (more than 50 % in some cases) presenting with
extrapulmonary disease. At very low CD4 counts, the
pulmonary features of disease may be completely absent
and disseminated TB may present as a nonspecific febrile
illness with high mortality, in which clinical diagnosis may
be completely missed and will only be discovered at
autopsy [39–42].
Diagnosis of tuberculosis
Robert Koch first used sputum microscopy and culture to
identify TB over 130 years ago. The diagnosis of active TB
in many parts of the world has still remained the same [43].
Although inexpensive and accessible, the technique is
operator dependent and has a poor sensitivity (45–80 %).
Sputum culture has a specificity of 98 %, but it takes
2–8 weeks for results to be available depending on culture
media and bacillary burden [44]. Furthermore, sputum is
difficult to collect from infants and children and the sensi-
tivity of microscopy of direct acid- and alcohol-fast stains is
low, often requiring multiple samples from an individual
before the diagnosis can be established [45, 46]. Sputum
culture is considered the golden standard for the diagnosis;
liquid media have largely replaced solid culture media, e.g.,
the Lowenstein–Jensen slope; liquid media have been
shown to considerably improve sensitivity and speed in
diagnosis of active TB [47]. The diagnosis of LTBI differs
from active TB. LTBI by definition refers to a clinical state
where one has Mtb infection without evidence of disease. It
is diagnosed by positive immunological response to pro-
teins of Mtb in the absence of clinical or radiological find-
ings. Traditionally, the Mantoux tuberculin skin test (TST)
has been used to assess the immunological response. This
test is conducted by injecting 0.1 ml of a tuberculin-purified
protein derivative by the intradermal route on the inner
surface of the forearm. This should produce a discrete pale
elevation of the skin of about 6–10 mm when done cor-
rectly. The test is read by measuring the diameter of the
induration of the skin produced. The test is interpreted along
with the clinical risk of the individual. While an induration
of more than 15 mm is positive, in a person with high risk
for disease such as contact with a TB patient a diameter of
10 mm is considered positive. The test has limitations of
being falsely negative in particularly immunocompromised
patients, while it gives false-positive results in other
patients with other mycobacteriosis or people who have had
previous vaccinations against TB [47].
Clin Transl Imaging (2016) 4:131–144 133
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Imaging in response to diagnostic limitations
Plain chest radiography (and in affluent settings, also CT)
are the mainstays for diagnostic imaging of pulmonary TB,
but are often nonspecific and unable to provide a definitive
diagnosis due to the heterogeneous presentation, particu-
larly in case of HIV co-infection when CD4 counts are low
[48–50]. On radiographs, primary TB is represented by
consolidation (Ghon focus), adenopathy and pleural effu-
sion. The Ghon focus most commonly occurs in the mid
and lower lung zones. When there is hilar lym-
phadenopathy in addition to the Ghon focus, a Ghon
complex is formed. The radiological features of reactiva-
tion TB include focal patchy opacities, cavitation, fibrosis,
nodal calcification and flecks of caseous material. These
commonly occur in the posterior segments of the upper
lobes and superior segment of the lower lobes of the lungs.
These features may be completely absent in patients with
severe immune deficiency. As a result of the limitations of
traditional diagnostics, new approaches have been devel-
oped. The interferon gamma release assay (IGRA) is a
blood test measuring cellular immune response to the TB
infection similar to the traditional tuberculin skin test
(TST), with similar sensitivity and improved specificity in
BCG-vaccinated individuals [51]. However, neither IGRA
nor TST is able to distinguish latent infection and active
disease and they are both dependent on host responses,
which may be compromised in immune-deficient patients
and children [52, 53]. Other new diagnostic methods
include urine LAM testing, which detects active TB in HIV
patients with high specificity, but modest sensitivity [54].
The Xpert MTB/RIF assay rapidly detects Mtb nucleic acid
in sputum, by targeting the rpoB-gene of Mtb, and at the
same time genetic mutations predicting rifampicin resis-
tance. It has a specificity of 98 %, but variable sensitivity
depending on the sputum bacterial load [55, 56]. Albeit
being useful for rapid initial diagnosis, it only establishes
susceptibility to rifampin and is inferior to culture for
monitoring treatment [57]. During treatment, subsets of
Mtb within the bacterial population that reflect naturally
occurring drug-resistant mutants may emerge. This usually
occurs during sub-optimal treatment with inadvertent
monotherapy. Most currently used diagnostic systems
including liquid culture fail to detect such subsets at the
start of treatment. Currently used diagnostic platforms
accept that if\1 % of the bacterial population is resistant
to a particular drug at one particular drug concentration
(the so-called breakpoint) that is generally accepted to be
achieved in blood by using the standard TB dosing regi-
men, that strain of Mtb should be considered susceptible to
that drug. The idea behind accepting Mtb at that breakpoint
is the assumption that by always using a regimen con-
taining three to five active drugs, the treatment will not fail
because the\1 % Mtb resistant to a particular drug will be
covered by other components of the drug regimen. Current
breakpoints recommended by EUCAST have recently been
questioned. In vitro hollow fibber models mimicking
plasma-drug concentration and population kinetics
demonstrated that an important subset of patients might not
reach target drug concentrations over time. These indi-
viduals may fail on regimes that according to the currently
used EUCAST breakpoint would have drug-susceptible
TB. Furthermore, very few of the currently available drugs
have efficacy in slowly replicating persistent organisms
[58, 59]. PET/CT may provide an important tool in the
detection of this subset of Mtb population.
18F-FDG PET
PET/CT has the ability to associate the pharmacological,
immunologic and microbiological aspects of TB lesions
with anatomic information, allowing a holistic approach to
understanding the disease [14]. The value of imaging TB
with 2-[18F]fluoro-2-deoxyglucose (18F-FDG) PET/CT has
been well documented [60–62]. 18F-FDG PET has been
used to detect TB granulomas and assess disease activity
[63, 64] and the extent of disease [65]. Efforts to use 18F-
FDG PET to distinguish benign from malignant lesions
have been made and results have generally not been
encouraging [66, 67]. Active TB avidly takes up 18F-FDG,
both in pulmonary and extrapulmonary lesions. Thus, 18F-
FDG PET can be very useful to assess the extent of active
TB. The detection of extrapulmonary lesions is particularly
useful, as obtaining tissue or fluid for analysis may not
always be possible or may be invasive. Many studies have
been conducted to distinguish avid TB from malignancy
and other granulomatous conditions [68–71]. Since 18F-
FDG is a nonspecific tracer, it cannot reliably distinguish
tuberculomas from malignant lung lesions and frequently
gives rise to a false-positive diagnosis in patients evaluated
for malignancy [72–74]. The overlap between the stan-
dardized uptake value (SUV) in malignant and benign
lesions has led to the investigation of several
dichotomization methods, such as the use of SUV cutoff
thresholds, dual tracer imaging, dual time point imaging
(DTPI) or delayed imaging. There is, however, no con-
sensus about the use of 18F-FDG PET to differentiate TB
from malignancy or other granulomatous or other inflam-
matory lesions. In a review, Cheng et al. point out that the
increased specificity of dual-time point imaging depends
on several factors and therefore recommend the selective
use of DTPI to improve the diagnostic accuracy and
interpretation confidence only in specific situations These
situations include obese, overweight or poorly controlled
diabetic patients who have high background uptake of 18F-
FDG [75]. It is important for the interpretation of an 18F-
134 Clin Transl Imaging (2016) 4:131–144
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FDG PET scan to have a high suspicion for TB, particu-
larly in a TB-endemic area or for an immigrant from an
endemic area now living in an area with low TB prevalence
[76]. Other studies have evaluated the use of 18F-FDG PET
in differentiating latent from active TB [77, 78]. TB has
recently been shown to be more dynamic than previously
thought [79, 80]. The infection occupies a more diverse
spectrum rather than simply latent and active disease
(Fig. 1). Thus, while high uptake in a lesion in a patient
with TB may represent active disease, it may also represent
a host immune system response that will eventually prevail
[78]. It is therefore prudent to exercise when interpreting
Fig. 1 18F-FDG PET/CT scan
before anti-TB treatment and
2 months after initiation of
treatment for interim assessment
of treatment response.
a Maximum intensity projection
(MIP) image before treatment
(PET images only), showing
extensive disease: pulmonary,
cervical, axillary, mediastinal,
abdominal, pelvic and inguinal
lymph nodes, hepatic and
skeletal metastasis to the lumbar
spine and right humerus. b MIP
image after 2 months of anti-TB
treatment (PET images only):
complete metabolic response of
the pulmonary and right
humeral lesions and the pelvic
and inguinal lymph nodes. Good
metabolic response in the
mediastinal, cervical and
axillary nodes. Active disease is
still present in the lumber spine
with progression of the hepatic
lesions. c Transverse scans
showing axillary nodes before
treatment (PET and integrated
PET/CT images). d Transverse
scans showing response of
axillary nodes after 2 month of
anti-TB therapy; nodal uptake
diminished but still present
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high 18F-FDG uptake as active TB in a patient with no
known history of active disease or symptoms of TB, but
only a positive tuberculin skin test or interferon gamma
release assay. 18F-FDG PET has also been used to evaluate
treatment response during and after therapy (Fig. 1).
Treatment of TB is a lengthy process, usually taking at
least 6 months, and resistant Mtb species are emerging. It is
important to have an early test to predict outcome early in
the course of treatment to enable timely change to appro-
priate therapy to prevent resistant species. 18F-FDG PET
has been shown to be very useful in monitoring treatment
response in this regard [81, 82]. Other studies also used
18F-FDG PET to assess response on completion of treat-
ment and some studies, in particular in the context of
MDR-TB, have shown patients remaining free of
TB months after completing treatment [83–85]. 18F-FDG
has also been evaluated and found to be useful for
assessing TB in specific organs of the body, such as
tuberculous infections of the skeleton. It has been shown to
help in distinguishing acute pyogenic from chronic tuber-
culous spondylitis [86–88]. 18F-FDG PET has, however,
not been useful in distinguishing TB from atypical TB,
sarcoidosis and HIV-associated lymphadenopathy [89–91].
An overview of original publications involving 18F-FDG
PET in more than one patient with TB is presented in
Table 1. The articles were found by entering PET/CT and
tuberculosis in medical Pubmed and all the references of
those articles were reviewed for additional references.
Publications including only one case were excluded.
Other PET tracers
Besides 18F-FDG, other PET tracers have been investigated
for imaging of TB, including 11C-choline, [18F]fluo-
roethylcholine (18F-FEC), 30-deoxy-30-[18F]fluoro-L-thy-
midine (18F-FLT), 68Ga-citrate, [18F] sodium fluoride (18F-
NaF) and radiolabeled anti-TB drugs (Table 2). The wall of
Mtb consists of many complex lipids. 11C-choline or 18F-
FEC can image the transportation and utilization of choline
in this lipid-rich envelope of Mtb. The incorporation of
thymidine into the DNA of bacteria can be imaged by the
thymidine analog 18F-FLT during the proliferation of Mtb.
The uptake of 68Ga-citrate by TB can be extrapolated from
studies with 67Ga-citrate and is dependent on specific and
nonspecific uptake mechanisms. Nonspecific mechanisms
include increased vascular permeability in areas of
inflammation, while specific factors include binding to the
siderophores the bacteria used to trap iron from hosts’
transferrin and other iron sources. 18F-NaF has a strong
binding affinity for calcium and can be used to visualize
micro-calcifications in old TB lesions. Drugs used for the
treatment of TB have also been labeled with radioisotopes
and can be used to study the biodistribution and pharma-
cokinetics of these drugs.
11C-Choline/18F-fluoroethylcholine
11C-Choline was evaluated for differentiation of lung
cancer and other lesions including active TB [66, 104,
105]. While 75 % accuracy was found when using 11C-
choline alone for this differentiation, combining 11C-cho-
line and F-FDG appeared to yield better results [105]. Both
tracers displayed a high uptake in malignant lesions. In TB,
however, 18F-FDG uptake was much higher than 11C-
choline uptake. The use of only one tracer may miss
extrapulmonary disease in areas where the tracers have a
physiologically high bio-distribution such as the brain for
18F-FDG and the liver for 18F-FEC [106]. 18F-FEC has
been suggested to be useful for evaluation of TB therapy.
30-Deoxy-30-18F-fluoro-L-thymidine
Prospective studies evaluating the diagnostic value of dual
tracer PET/CT in pulmonary lesions using 18F-FLT and
18F-FDG PET noted that 18F-FLT PET is most useful when
combined with 18F-FDG PET. This yielded more infor-
mation than either tracer used alone. Visual inspection of
images and the ratio of the maximum SUV between 18F-
FLT and 18F-FDG improved the diagnostic accuracy in
distinguishing malignant from benign lesions including
tuberculosis [107, 108].
68Ga-citrate
68Ga-citrate was shown to have good uptake in both pul-
monary and extrapulmonary TB lesions and was useful in
distinguishing active lesions from inactive lesions. How-
ever, the uptake was nonspecific, as it was unable to dis-
tinguish malignant from benign lesions [109, 110]. 68Ga-
citrate is potentially a very useful tracer to stage disease in
cases where the diagnosis is already known. Further studies
are needed to see if 68Ga-citrate will have the same use as
demonstrated by 18F-FDG (Table 1). 68Ga-citrate holds
promise particularly in middle income and or even devel-
oping economies where PET/CT may be available, because
68Ga is produced from a generator rather than from a
cyclotron. The expense and high technical demands for
running a cyclotron have been obviated and the tracer will
be readily available.
18F-sodium fluoride
A study demonstrated in a murine model of chronic TB the
usefulness of 18F-NaF in detecting micro-calcifications,
136 Clin Transl Imaging (2016) 4:131–144
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Table 1 Original articles on the use of 18F-FDG PET in TB
Journal/year 1st author Use No. of TB
pts/pts
studied
Major finding of 18F-FDG and TB Sens (%) Spec (%)
Ann Nuc Med 1996 Ichiya et al. [63] 1, 6 8/24 Detected and assessed activity in TB lesions, but
was unable to distinguish TB from MAC*
na Na
Radiology 2000 Goo et al. [64] 1, 3 10/10 Active tuberculomas were 18F-FDG avid and
caused false positives in cancer evaluation
na Na
Chest 2003 Hara et al. [66] 1, 3,
6
14/116 TB, atypical TB and cancer were discriminated
by performing both 18F-FDG and 11C-choline
PET scans
na Na
Neoplasia 2005 Mamede et al. [67] 1, 3 10/60 Uptake correlated with inflammation of TB
lesions causing false-positive results in cancer
87–97.8 Na
Tuberculosis 2007 Hofmeyr et al.
[83]
3, 5 2/2 Was useful in TB diagnosis in high-risk patients
and in monitoring anti-TB treatment
na Na
Clin Nuc Med 2008 Park et al. [84] 5 2/2 Was useful in assessing response to anti-TB
therapy in patients with tuberculoma
na Na
EJNMMI 2008 Yen et al. [68] 3 8/96 TB was a major cause of false positives in
evaluating lymph nodes in lung cancer
73.8 88.9
EJNMMI 2008 Kim et al. [75] 4 25/25 Assessed TB activity by visual assessment and
SUV change from early to delayed scan
71.4–100 81.8–100




25/47 Distinguished latent TB from active TB and in
monitoring anti-TB therapy response
na Na
Nuc Med Comun 2009 Castaigne et al.
[103]
1, 6 6/10 Was useful in detecting TB as a cause of fever of
unknown origin in HIV patients
na Na
Pediatr Surg Int 2009 Hadley et al. [68] 3, 6 3/18 Was a major cause of false positive for cancer in
HIV children
na Na
Spine 2009 Kim et al. [86] 5, 6 11/30 Had prognostic value in anti-TB therapy of the
spine and detected residual disease
85.7–100 68–82.6
Lung 2010 Hahm et al. [90] 1, 6 26/41 Was unable to distinguish TB from MAC na Na
World J Gastroenterol
2010
Tian et al. [70] 3 3/3 Was a cause of false positive in assessing
abdominal malignancy
na Na
Nuklearmedizin 2010 Sathekge et al.
[65]
2, 7 16/16 Detected more extensive disease when compared
to contrast-enhanced CT
na Na
Acta Radiol 2010 Tian et al. [92] 5 3/3 Was useful in assessing response to treatment in
non-pulmonary TB
na Na
S Afr Med J 2010 Sathekge et al.
[93]
3 12/30 Was not useful in differentiating benign from
malignant lesions in a TB-endemic area
87 25–100
QJNMMI 2010 Sathekge et al.
[89]
3, 6 37/83 Was not useful for assessing malignancy in lymph




Kim et al. [87] 6 8/23 Was useful in distinguishing TB spondylitis from
pyogenic spondylitis
86.6 62.9
Ann Nuc Med 2011 Li et al. [94] 3 8/96 TB caused high false positives for cancer with





Kumar et al. [95] 1, 3 12/35 Increased SUV cutoff improved specificity and
with acceptable sensitivity in mediastinal node
evaluation
87–93 40–70
J Korean Med Sci 2011 Lee et al. [71] 3, 6 54/54 Found low accuracy in the evaluation of lung
cancer pts with parenchymal sequelae from
previous TB
60 69.2




24/24 Was useful to predict HIV patients who would
respond to anti-TB therapy
88 81
Eur J Rad 2012 Soussan et al. [96] 2 16/16 Found 2 distinct patterns of pulm TB uptake na Na
EJNMMI 2012 Sathekge et al.
[97]
5, 7 20/20 Was useful in distinguishing lymph nodes
responding to anti-TB from those that did not
88–95 66–85
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which were not visualized by CT. This approach could
potentially be applied in humans and help distinguish acute
from chronic TB [111].
11C-radiolabeled drug tracers
Some chemotherapeutic agents for treatment of tubercu-
losis, including isoniazid, rifampicin and pyrazinamide,
have been labeled with carbon-11 (11C) and their biodis-
tribution, in particular their ability to cross the blood–brain
barrier, has been evaluated in nonhuman primates. There
have not been any corresponding human studies with these
tracers till date. The radiolabeled chemotherapeutic agents
were used to show whether the drug achieved a sufficiently
high concentration in infected sites, particularly in TB
meningitis and TB brain abscesses. This is an important
finding, as TB of the central nervous system is usually life
threatening and requires long periods of treatment (usually
a year) and may sometimes need to be continued even
when adverse effects develop. These radiolabeled drug
tracers were not assessed for detection of TB [112].
Treatment of TB
The treatment of TB depends on whether the individual has
active or LTBI. Treatment of active TB requires long-term
multidrug therapy to overcome tolerance, achieve bacterial
clearance and reduce the risk of transmission. Tolerance is
an epigenetic drug resistance widely attributed to non-
replicating bacterial subpopulations [113]. The drugs are
classified as first- and second-line agents. First-line
agents—class 1, WHO—include isoniazid and rifampicin,
Table 1 continued
Journal/year 1st author Use No. of TB
pts/pts
studied
Major finding of 18F-FDG and TB Sens (%) Spec (%)




5 21/21 Was useful in evaluating early therapeutic
response to anti-TB
na Na
BMC Pulm Med 2013 Heysell et al. [78] 2, 4 4/4 Demonstrated the usefulness in the management
of high-risk TB pts who are sputum negative
na Na
Eur Spine J 2014 Dureja et al. [88] 5 33/33 SUVmax was found to be a quantitative marker
for response in spinal TB
na Na
Sci Trans Med 2014 Coleman et al.
[99]
5 18/18 Demonstrated usefulness of assessing the
response of anti-TB in macaques and pts with
XDR-TB
96 75
J Korean Med Sci 2014 Jeong Y-J et al.
[100]
1 63/63 Found pts with old healed lesions with high SUV
to be at risk for development of active TB
na Na
Sci Trans Med 2014 Chen et al. [85] 5 28/28 Demonstrated that changes at 2 months of anti-
TB are early predictors of the final outcome in
MDR-TB
na Na
Chest 2014 Maturu et al. [91] 6 29/117 Did not find any significant difference in the




Huber et al. [101] 3, 6 122/207 Found more likely to detect cancer in the
evaluation of granulomatous lesions in
pts[ 60 years
na Na
EJNMMI 2015 Fuster D et al.
[102]
7 4/26 Recommended 18F-FDG should be considered
first line in the imaging of spondylodiscitis
83 88
When an article evaluated more than one feature of TB, then the sensitivity and specificity apply to the use indicated by the number highlighted
in italics and bold
Pts patients, MAC Mycobacterium avium complex
* Pulm pulmonary
1 To detect TB lesions and assess disease activity
2 To assess the extent of disease
3 To assess the effect of TB on cancer staging or diagnosis with 18F-FDG
4 To differentiate latent from active TB
5 To monitor treatment response
6 To assess the ability to differentiate TB from nonmalignant conditions, including atypical mycobacteria, as well as to assess the effect TB has
on 18F-FDG imaging of nonmalignant conditions
7 To compare the detection of TB by PET with other modalities
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the two most potent anti-TB agents. Resistance to these
agents defines a case of MDR-TB. Second-line agents are
divided by the WHO into four different classes (WHO
class 2–5); class 2 includes the injectables amikacin,
kanamycin and capreomycin; class 3 are the fluoro-
quinolones; class four includes less potent, more toxic oral
agents; and class 5 includes agents with as yet unknown
significance. Only if Mtb isolates are susceptible, the
treatment may last 6 months. Patients with large cavitary
lesions that have delayed sputum culture conversion, those
with M. bovis disease that is naturally nonsusceptible to
pyrazinamide, those who cannot tolerate pyrazinamide and
those with meningitis TB need treatment prolongation to
9 months. The so-called ‘‘short course’’ of 6 months for
drug-susceptible TB is a major advance, as previous ther-
apies lasted 12–18 months. Treatment is still challenging,
as adhering to a multidrug regimen for 6 months has been
shown to be difficult, especially in low-resource settings
[114]. Despite the presence of several new drugs under
investigation, attempts to shorten the treatment still remain
elusive [115]. This failure highlights the poor understand-
ing of the tolerance of Mtb. The WHO recommends iso-
niazid and rifampicin for treatment of drug-susceptible
infections. The treatment is in two phases: initiation and
continuation. The initiation phase treatment usually
contains four first-line agents including rifampicin and
isoniazid for 2 months, and the continuation phase consists
of isoniazid and rifampicin only for the last 4 months of
treatment. The current guidelines recommend the directly
observed treatment (DOTS) strategy to improve adherence.
This strategy involves patients taking medication under
supervision. Although this has greatly improved the suc-
cess of treatment, the emergence of drug resistance could
not be curbed with this strategy. There are also guidelines
for drug-susceptibility testing to rapidly diagnose and
appropriately treat MDR-TB [116]. Although the treatment
outcome of drug-susceptible TB has been fair, with suc-
cessful outcome reported by most countries at around
85 %, the outcome of MDR-TB treatment has generally
been poor, with successful outcome reported under service
conditions at around 50 % only [2]. The reported series do
slightly better at around 60 % [117] and only few national
programs attain success rates at around the target set for
drug-susceptible TB [118].
In patients with LTBI, treatment is recommended for
persons deemed to be at high risk of developing active
disease. It is important that treatment is only initiated after
active disease has been excluded by clinical and radio-
graphic means. A failure to do so will result in inadequate
treatment and development of resistant species. The
Table 2 Mechanism of PET tracer uptake in TB
Tracer Clinical or pre-clinical
(animal model used)
Mechanism of uptake Use(s)
18F-fluoro-deoxy-glucose
[60–103]
Clinical Uptake during the respiratory burst by
activated inflammatory cells as by glucose
transporters and is phosphorylated to FDG-
6-phospate and remains trapped in the cell
Assesses disease activity, staging
(especially extrapulmonary) monitoring




Clinical Uptake during the synthesis of the complex
lipid layer of the cell wall
Combined with FDG, helps distinguish




Clinical Uptake during the synthesis of nucleic acids
as bacteria proliferates
Combined with FDG, helps distinguish
TB from malignancy
68Ga-citrate [109, 110] Clinical Accumulates in bacterial siderophores of Mtb
and in plasma lactoferrin similar to 67Ga-
citrate and also accumulates by nonspecific
mechanisms as increased vascular
permeability
Detects TB lesions and may be better than
CT in the detection of extrapulmonary
lesions
11F-sodium fluoride [111] Preclinical (mice) Binds to micro-calcification in chronic TB
lesions
Potentially helps to distinguish acute from
chronic TB
11C-Rifampicin [112] Preclinical (baboons) Binds to (and inhibits) Mtbs DNA-dependent
RNA polymerase
Determines whether there is adequate
accumulation of drug in the infected site
11C-Isoniazid [112] Preclinical (baboons) Binds to Mtb enzymes and generates reactive
oxygen species resulting in inhibition of
cell wall lipid synthesis and depletion of
nucleic acid pools and metabolic depression
Determines whether there is adequate
accumulation of drug in the infected site
11C-Pyrazinamide [112] Preclinical (baboons) Binds to cell membrane proteins, disrupts
membrane energetics and inhibits
membrane transport functions in Mtb
Determines whether there is adequate
accumulation of drug in the infected site
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preferred treatment is isoniazid daily for 9 months. The
WHO recently developed the guidelines for latent TB
treatment. The identification of people at risk considers
factors such as the level of income of a country, prevalence
of TB in a country, presence of other diseases, conditions
like HIV infection and use of gamma interferon. Other
guidelines combine these conditions with the size of
induration after a tuberculin skin test [2, 119, 120].
Conclusions and future perspectives
18F-FDG PET/CT is a sensitive noninvasive biomarker for
the detection, staging, assessing disease activity and mon-
itoring therapy in TB. The complex and long period
required for the treatment of TB makes 18F-FDG PET
particularly useful, as it is able to detect at an early point in
treatment drug combinations that are ineffective and lead to
a change in therapy. This is not only important to reduce
morbidity and mortality in the individual, but prevents the
even greater public health hazard of the individual devel-
oping resistant species of Mtb and transmitting the resistant
strain in the community.
PET/CT provides a unique opportunity for the in vivo
histological characterization of TB lesions. This role is
becoming more and more important as the molecular basis
of TB is elucidated. These tracers provide an ideal platform
for personalized medicine in TB treatment. PET/CT has
played and continues to play a major role in the develop-
ment of new drugs and therapeutic strategies like vaccines.
This role will hopefully expand in the future with the
development of new tracers and repurposing of existing
tracers. For example, MDR-TB and LTBI have hypoxia as
one of the main processes underlying their pathology. The
antibiotic metronidazole that is a pro-drug activated by
hypoxia has been shown to be useful in the treatment of
MDR-TB [121]. Hypoxic PET tracers already validated for
the management of cancer could potentially play a role in
the management of TB. In conclusion, PET/CT has
demonstrated its usefulness in managing different aspects
of tuberculosis disease and the development of new ther-
apeutic interventions. The role of PET/CT is likely to grow
further as we aim to eradicate TB by 2015 [2].
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